The company maintains a conservative capital structure with a low debt-to-equity ratio of 0.06 as of 2025Q4, supported by a total equity base of $312.1M that provides significant financial flexibility.
| Metric | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Total Current Assets | 305.02M | 386.26M | 347.2M | 386.19M | 501.81M | 414.35M | 168.84M | 259.79M | 198.11M | 288.15M | 318.2M | 223.72M | 12.14M | 13.54M |
| Cash & Short-Term Investments | 278.89M | 367.31M | 327.14M | 350.1M | 465.71M | 403.88M | 162.45M | 250.88M | 189.67M | 282.37M | 314.53M | 220.13M | 9M | 12.03M |
| Cash Only | 254.07M | 280.64M | 191.08M | 149.87M | 465.71M | 403.88M | 132.36M | 117.05M | 72.65M | 62.96M | 134.75M | 218.96M | 7.17M | 10.86M |
| Short-Term Investments | 24.83M | 86.67M | 136.06M | 200.23M | 0 | 0 | 30.09M | 133.83M | 117.03M | 219.41M | 179.78M | 1.17M | 1.83M | 1.18M |
| Accounts Receivable | 8.13M | 12.9M | 2.38M | 22.36M | 3.59M | 2.94M | 2.33M | 1.33M | 1.8M | 125K | 706K | 1.75M | 2.67M | 575K |
| Days Sales Outstanding | 636.93 | 975.48 | 260.43 | 3.9K | 131.27 | 128.61 | 97.76 | 29.61 | 1.01K | 10.3 | 21.95 | 317.47 | 138.84 | 26.46 |
| Inventory | 0 | 0 | 0 | 0 | 28M | 0 | 0 | -1.33M | -2.72M | -1.92M | 0 | -1.75M | -2.67M | 0 |
| Days Inventory Outstanding | - | - | - | - | 92.51 | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 11.42M | 1.64M | 13.37M | 2.12M | -6.24M | 2.12M | 2.12M | 2.2M | 927K | 897K | 896K | 0 | 0 | 0 |
| Total Non-Current Assets | 229.69M | 216.38M | 346.77M | 316.45M | 444.2M | 575.64M | 772.33M | 181.98M | 141.74M | 10.6M | 8.55M | 4.31M | 4.63M | 5.64M |
| Property, Plant & Equipment | 11.5M | 15.13M | 19.36M | 37.24M | 43.94M | 42.87M | 43.84M | 8.32M | 6.86M | 6.92M | 4.52M | 1.23M | 1.21M | 1.08M |
| Fixed Asset Turnover | 0.41x | 0.32x | 0.17x | 0.06x | 0.23x | 0.19x | 0.20x | 1.97x | 0.09x | 0.64x | 2.60x | 1.64x | 5.79x | 7.37x |
| Goodwill | 601K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 601K | 906K | 831K | 987K | 899K | 625K | 3.08M | 3.31M | 3.52M | 3.87M | 3M | 3.16M | 3.34M |
| Long-Term Investments | 217.43M | 200.17M | 325.63M | 60.81M | 398.46M | 531.86M | 695.46M | 35.93M | 14.33M | -219.32M | -179.68M | -1.09M | -1.58M | 40K |
| Other Non-Current Assets | 166K | 476K | 879K | 278.38M | 399.27M | 531.87M | 32.27M | 134.2M | 117.1M | 65K | 57K | 5K | 3K | 9K |
| Total Assets | 534.71M | 602.63M | 693.97M | 702.65M | 946.01M | 989.99M | 941.18M | 441.76M | 339.85M | 298.75M | 326.75M | 228.03M | 16.77M | 19.18M |
| Asset Turnover | 0.01x | 0.01x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.04x | 0.00x | 0.01x | 0.04x | 0.01x | 0.42x | 0.41x |
| Asset Growth % | -11.27% | -13.16% | -1.23% | -25.72% | -4.44% | 5.19% | 113.05% | 29.99% | 13.76% | -8.57% | 43.3% | 1260.06% | -12.61% | - |
| Total Current Liabilities | 46.31M | 41.39M | 51.37M | 96.89M | 226.13M | 180.92M | 139.2M | 265.76M | 273.86M | 204.08M | 160.52M | 93.67M | 22.76M | 21.43M |
| Accounts Payable | 3.07M | 5.52M | 14.64M | 26.5M | 11.35M | 8.87M | 11.1M | 4.64M | 3.39M | 2.08M | 2.39M | 1.61M | 905K | 1.19M |
| Days Payables Outstanding | - | - | 1.08K | 63.46 | 37.48 | - | 47.19 | 21.9 | 17.44 | 482.87 | 1.18K | - | - | - |
| Short-Term Debt | 8.67M | 4.11M | 3.7M | 7.5M | 5.5M | 26.45M | 1.46M | 12.01M | 7.46M | 6.95M | 4.96M | 6.95M | 4.26M | 1.46M |
| Deferred Revenue (Current) | 0 | 0 | -29.47M | 2.19M | 31.32M | 141.61M | 22.21M | 30.8M | 129.01M | 88.38M | 87.05M | 70.21M | 7.45M | 10.91M |
| Other Current Liabilities | 31.54M | 27.18M | 29.64M | 29.4M | 152.01M | -529K | 92.45M | 207.08M | 121.04M | 97.62M | 61.29M | 11.78M | 9.14M | 12.53M |
| Current Ratio | 6.59x | 9.33x | 6.76x | 3.99x | 2.22x | 2.29x | 1.21x | 0.98x | 0.72x | 1.41x | 1.98x | 2.39x | 0.53x | 0.63x |
| Quick Ratio | 6.59x | 9.33x | 6.76x | 3.99x | 2.10x | 2.29x | 1.21x | 0.98x | 0.73x | 1.42x | 1.98x | 2.41x | 0.65x | 0.63x |
| Cash Conversion Cycle | - | - | - | - | 186.3 | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 182.73M | 153.31M | 184.37M | 58.17M | 135.72M | 155.53M | 151.58M | 9.03M | 1.99M | 2.26M | 2.18M | 668K | 2.03M | 1.11M |
| Long-Term Debt | 0 | 0 | 0 | 10.24M | 14.26M | 14.82M | 0 | 357K | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 11.09M | 14.67M | 18.25M | 24.16M | 29.04M | 32.09M | 34.91M | 357K | 410K | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 52.46M | 19.64M | 89.77M | 108.63M | 115.44M | 6.43M | 4.4M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 171.64M | 138.64M | 113.66M | 4.13M | 2.66M | -1K | 0 | 876K | 1.42M | 2.06M | 1.89M | 107K | 501K | 48K |
| Total Liabilities | 229.03M | 194.7M | 235.74M | 155.06M | 361.86M | 336.45M | 290.78M | 274.79M | 275.85M | 206.34M | 162.7M | 94.34M | 24.79M | 22.54M |
| Total Debt | 19.76M | 22.36M | 25.34M | 46.87M | 52.75M | 76.62M | 39.3M | 12.37M | 7.46M | 6.95M | 4.96M | 6.95M | 4.26M | 1.46M |
| Net Debt | -234.31M | -258.28M | -165.74M | -102.99M | -413.68M | -327.26M | -93.06M | -104.68M | -65.19M | -56.01M | -129.8M | -212.01M | -2.91M | -9.4M |
| Debt / Equity | 0.06x | 0.05x | 0.06x | 0.09x | 0.09x | 0.12x | 0.06x | 0.07x | 0.12x | 0.08x | 0.03x | 0.05x | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -1.42x | 3.37x | -1.23x | -50.04x | 4.13x | 19.02x | 117.29x | -4.60x | -6.85x | -11.22x | -11.95x | -28.38x | -13.47x | -16.70x |
| Total Equity | 305.68M | 407.93M | 458.23M | 547.59M | 584.15M | 653.54M | 650.4M | 166.97M | 64M | 92.41M | 164.05M | 133.69M | -8.03M | -3.35M |
| Equity Growth % | -25.07% | -10.98% | -16.32% | -6.26% | -10.62% | 0.48% | 289.53% | 160.91% | -30.75% | -43.67% | 22.71% | 1765.47% | -139.33% | - |
| Book Value per Share | 126.95 | 15.13 | 16.58 | 19.23 | 20.38 | 22.32 | 22.29 | 6.10 | 2.68 | 4.03 | 8.85 | 16.21 | -1.26 | -0.53 |
| Total Shareholders' Equity | 312.07M | 414.71M | 464.07M | 542.22M | 593.51M | 669.75M | 668.04M | 275.51M | 214.3M | 177.67M | 226.12M | 179M | -884K | 3.09M |
| Common Stock | 4.86M | 4.86M | 5.46M | 5.46M | 5.44M | 5.42M | 5.41M | 5.38M | 4.68M | 4.61M | 4.52M | 159.36M | 1.27M | 1.27M |
| Retained Earnings | 61.27M | 32.49M | 83.82M | 149.52M | 199.87M | 260.43M | 254.44M | -167.69M | -127.87M | -160.34M | -111.42M | -70.42M | -35.06M | -30.9M |
| Treasury Stock | -41.15M | -46.86M | -44.63M | -26.49M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 182K | 133.96M | 129.15M | -14.39M | -39.61M | -23.58M | -18.28M | -6.07M | -3.88M | -2.24M | -1.05M | -649K | -457K | -337K |
| Minority Interest | -6.4M | -6.77M | -5.83M | 5.37M | -9.37M | -16.21M | -17.64M | -108.53M | -150.31M | -85.25M | -62.07M | -45.32M | -7.14M | -6.45M |
Clinical trial binary outcomes
As reported in financial statements, PureTech's total assets have declined from $946.0M in 2021Q4 to $534.7M by 2025Q4, a trend that appears to be driven by the strategic divestiture of founded entities and the subsequent realization of value rather than operational deterioration of the core platform.
The reduction in the asset base suggests a transition from a portfolio-heavy model toward a more focused internal development strategy. Investors should monitor whether this contraction stabilizes as the company shifts its capital allocation toward its wholly-owned pipeline assets.
Based on reported figures, PureTech maintains a conservative capital structure with total debt of $19.8M against $312.1M in equity as of 2025Q4, resulting in a low debt-to-equity ratio of 0.06 that indicates minimal reliance on external credit to fund its ongoing research activities.
The company's limited debt burden suggests that it is not currently constrained by interest obligations, providing management with significant flexibility to navigate clinical trial timelines. This low leverage profile appears to be a strategic choice to avoid the risks associated with debt-servicing in a high-burn, pre-revenue environment.
According to recent SEC filings, PureTech holds $254.1M in cash as of 2025Q4, which, when paired with a current ratio of 6.59, suggests a robust liquidity position that provides a substantial buffer against the inherent volatility of clinical-stage biotechnology development and operational cash burn.
The high current ratio indicates that the company is well-positioned to meet its short-term obligations without needing to access capital markets under unfavorable conditions. This liquidity cushion appears sufficient to support the current R&D trajectory, though investors should remain mindful of the burn rate as clinical programs advance.
As evidenced by historical data, PureTech's retained earnings have fluctuated significantly, moving from $199.9M in 2021Q4 to $61.3M in 2025Q4, a pattern that reflects the periodic recognition of gains from equity exits and the subsequent reinvestment into the company's internal therapeutic discovery platform.
The volatility in equity quality suggests that the company's book value is highly sensitive to the success of its founded entities. This implies that the balance sheet's strength is currently tied more to the performance of external investments than to the accumulation of organic, recurring operational profits.
Quick answers to the most common questions about buying PRTC stock.
As of 2025, PureTech Health plc (PRTC) had total assets of $534.7M including $305.0M in current assets.
PureTech Health plc (PRTC) carries total debt of $19.8M, offset by $278.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
PureTech Health plc (PRTC) has total shareholders' equity (book value) of $312.1M ($126.95 book value per share). Book value represents the net worth of the company belonging to common stock holders.
PureTech Health plc (PRTC) reported a current ratio of 6.59x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.